Literature DB >> 30926306

Prevention of delayed hemolytic transfusion reaction.

F Pirenne1.   

Abstract

Post-transfusion hemolysis is the most frequent immune reaction to transfusion in sickle cell disease. Its frequency is underestimated due to its biological and clinical characteristics. It results principally from the high incidence of alloimmunization in these patients, but no antibodies are detectable in 30% of cases. Prevention is based on the prevention of alloimmunization through the use of matched RBCs for highly immunogenic blood groups, taking into account the patient's transfusion history, particularly in patients undergoing occasional transfusion, which is associated with a higher risk of DHTR development than chronic transfusion. In addition to the use of matched RBCs, the prevention of alloimmunization through immunotherapy should be considered.
Copyright © 2019. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Alloimmunisation; Alloimmunization; Drépanocytose; Post-transfusion hemolysis; Prevention; Réaction hémolytique post-transfusionnelle; Sickle cell disease; Transfusion

Mesh:

Substances:

Year:  2019        PMID: 30926306     DOI: 10.1016/j.tracli.2019.02.007

Source DB:  PubMed          Journal:  Transfus Clin Biol        ISSN: 1246-7820            Impact factor:   1.406


  3 in total

1.  Delayed Hemolytic Transfusion Reaction in a Patient with Sickle Cell Disease: Case Report.

Authors:  Sawsan A Omer; Jafar S Alaesh; Kefah B Algadeeb
Journal:  Int Med Case Rep J       Date:  2020-07-28

2.  Application of Salvage Autologous Blood Transfusion for treating Massive Hemorrhage during Ectopic Pregnancy.

Authors:  Junying Li; Hequn Jin; Zhen Hu
Journal:  Front Surg       Date:  2022-05-06

3.  Alloimmunization in dogs after transfusion: A serial cross-match study.

Authors:  Lisa Herter; Christiane Weingart; Nina Merten; Nicole Bock; Roswitha Merle; Barbara Kohn
Journal:  J Vet Intern Med       Date:  2022-08-19       Impact factor: 3.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.